#ESMO26 @AndreaNecchi presented ENERGIZE (CA017-078), comparing perioperative nivolumab + gemcitabine/cisplatin vs GC alone (N=653).

Julian Chavarriaga· @chavarriagaj · X·2026-10-23 22:59· 2 天前评分70

正文 · 机器翻译

#ESMO26 @AndreaNecchi 展示了 ENERGIZE (CA017-078)，比较围手术期 nivolumab + gemcitabine/cisplatin 与单用 GC (N=653).

🔹 pCR：39.1% 对 29.6%，但未达到统计学阈值
🔹 EFS：HR 0.94；p=0.67
🔹 OS：HR 0.88（描述性）
🔹 Grade ≥3 AEs：73% 对 56%
🧬 ctDNA 清除对 EFS 和 OS 有强预后意义，但无论基线 ctDNA 状态还是清除情况，均未识别出从 nivolumab 获益更多的患者。
@UroToday @myESMO

304 浏览 · 4 赞 · 4 转发 · 0 回复

会议摘要

2081PNCT04949113 NCT04949113 NCT04949113按 Melanoma 对上

Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity

https://esmocongress.esmo.org

4736O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)

https://esmocongress.esmo.org

4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)

https://esmocongress.esmo.org

LBA54按 Proffered paper: Melanoma and other skin tumours 对上

Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：Julian Chavarriaga · x.com